CurrentCardio
Get Weekly

Stay current with cardiology research.

Structured Briefs, a personalized Weekly, and a searchable archive of clinically relevant studies from leading journals.

Free35 journals16,412 BriefsFounded by a cardiovascular researcher, MD

Personalized updatesFollow what interests youChoose your topics, journals and study designs. See matching new studies in My Week, or receive them in a personalized weekly e-mail.Choose what to follow Searchable archiveFind relevant researchStructured cardiology Briefs from leading journals. Search by keyword or filter by topic, study design, journal and date.Explore the archive
Read the full issue

Week 44 · studies published 26 October – 1 November 2026

  1. The Lancet

    Meta-analysisCoronary & ACS

    Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trials

    0/1 h versus 0/3 h pathways

    Primary safety outcome: all-cause death or new type 1 myocardial infarction

    random-effects pooled OR 0.8395% CI 0.45–1.53

    0/1 h pathwayvs 0/3 h pathway
    random-effects pooled OR 0.83 (95% CI 0.45–1.53)

    Read the Brief

  2. JAMA

    Randomized controlled trialArrhythmias & EP

    Left Bundle-Branch Area Pacing vs Right Ventricular Pacing for Atrioventricular Block and Preserved Left Ventricular Function: The LEAP-Block Randomized Clinical Trial

    Left bundle-branch area pacing (LBBAP) vs right ventricular pacing (RVP)

    Composite of all-cause death, heart failure (HF) events, or upgrade to biventricular pacing

    LBBAP vs RVPAbsolute risk difference (95% CI)P value
    Composite of all-cause death, HF events, or upgrade to biventricular pacing
    −10.1%(−16.8% to −3.4%)
    P = 0.003

    Read the Brief

  3. Circulation

    Randomized controlled trialValvular & structural

    Transcatheter Aortic Valve Replacement in Pure Aortic Regurgitation: The Randomized SEASON-AR Clinical Trial

    transfemoral transcatheter aortic valve replacement (TAVR) with the VitaFlow system plus guideline-directed medical therapy (GDMT) or GDMT alone

    Primary result

    HR 0.3195% CI 0.14–0.66 · P = 0.001

    TAVR groupvs GDMT group
    HR 0.31 (95% CI 0.14–0.66); P = 0.001

    Read the Brief

Just published

More in Explore